Turn Biotechnologies vs ImmunoVec
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $29M Series A. Acquired ARMMs vesicular delivery tech (Mar 2025). Delivers mRNA cocktails that transiently reprogram aged cells to youthful epigenetic states without altering DNA.
About
Turn Biotechnologies is a longevity company using modified mRNA cocktails to transiently reprogram aged cells back toward a youthful epigenetic state — without permanently altering DNA sequences. The company has raised $29 million in Series A financing and acquired ARMMs (Arrestin Domain-Containing Protein 1 Mediated Microvesicle) technology in March 2025 to significantly upgrade the delivery capability of its mRNA reprogramming platform.
Received up to $40.7M ARPA-H award (Oct 2025). Polymeric nanoparticle platform to reprogram immune cells in vivo without viral vectors. Non-viral delivery for CAR-T-like therapies.
About
ImmunoVec is developing a non-viral polymeric nanoparticle delivery platform for in vivo immune cell engineering — programming a patient's immune cells directly inside their body without the expensive ex vivo manufacturing process that makes CAR-T therapies cost $500,000-$1,000,000 per treatment. The company received a selective ARPA-H (Advanced Research Projects Agency for Health) award of up to $40.7 million in October 2025 for development of its platform.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.